Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Q3 2026 Earnings Presentation
16 slides from Bristol-myers Squibb's earnings presentation, Oct 29, 2026
Slide 1: Q3 2026 Results
Not for Product Promotional Use Q3 2026 Results October 29, 2026
Slide 2: Forward Looking Statements and Non-GAAP Financial Information
Not for Product Promotional UseQ3 2026 Results Forward Looking Statements and Non-GAAP Financial Information 2 This presentation (as well as the oral statements made with respect to information contained herein) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financia
Slide 3: Q3 2026 Results - Chris Boerner, CEO
3 Q3 2026 Results Chris Boerner, PhD Board Chair and Chief Executive Officer
Slide 4: Q3 2026 Performance: Growth Portfolio Revenues and Key Milestones
Not for Product Promotional UseQ3 2026 Results Q3 2026 Performance *See “Forward-Looking Statements and Non-GAAP Financial Information” 1. Not an exhaustive list of assets, programs, or indications $6.9 $7.7 Q3 2025 Q3 2026 $ in billions 4 Growth Portfolio Revenues Key Milestones1 +12%; +12% Ex-FX*
Slide 5: Significant data expected in 2026 and beyond
Q3 2026 Results Not for Product Promotional Use Significant data expected in 2026…and beyond* NME registrational data 2026 • Admilparant IPF (ALOFT-IPF) (Oct ’26) • Arlo-cel 4L+ MM (QUINTESSENTIAL) (Sept ’26) • Iberdomide RRMM PFS (EXCALIBER-RRMM) (Oct ’26) • Mezigdomide RRMM (SUCCESSOR-2) (Mar ’26)
Slide 6: Key Priorities Through Year-End and Beyond
Q3 2026 Results Not for Product Promotional Use Key Priorities Through Year-End and Beyond* Sustain Growth Portfolio momentum 8 medicines annualizing at >$1B, providing a broad base of growth drivers Solidifying the Growth Profile Filings, approvals and launches, as exemplified by Zenbexus, to bring
Slide 7: Q3 2026 Results - David Elkins, CFO
7 Q3 2026 Results David Elkins Executive Vice President and Chief Financial Officer
Slide 8: Growth Portfolio continues to drive revenues
Q3 2026 Results Not for Product Promotional Use $ in billions Growth Portfolio continues to drive revenues Other Growth Brands1 Growth Portfolio Legacy Portfolio Other Mature Brands $6.9 $7.7 5.4 5.4 Q3 2025 Q3 2026 $12.2 $13.1 +12% YoY +12% Ex-FX* 8 *See “Forward-Looking Statements and Non-GAAP Fin
Slide 9: Q3 2026 Oncology product summary
Not for Product Promotional UseQ3 2026 Results Q3 2026 Oncology product summary *See “Forward-Looking Statements and Non-GAAP Financial Information”; 1. Abraxane: Q3 2026 WW Sales $65M - YoY% (13%), (12%) Ex-FX* Global Net Sales1 $M YoY % Ex-FX* % $2,374 (6%) (6%) $793 +7% +8% $367 +23% +23% $334 >2
Slide 10: Q3 2026 Hematology product summary
Not for Product Promotional UseQ3 2026 Results Global Net Sales1 $M YoY % Ex-FX* % $750 +22% +22% $526 +46% +48% $303 (47%) (47%) $130 (81%) (80%) Q3 2026 Hematology product summary *See “Forward-Looking Statements and Non-GAAP Financial Information”; 1. Abecma: Q3 2026 WW Sales $76M - YoY% (44%), (
Slide 11: Q3 2026 Cardiovascular & Immunology product summary
Not for Product Promotional UseQ3 2026 Results Q3 2026 Cardiovascular & Immunology product summary Global Net Sales (Cardiovascular) $M YoY % Ex-FX* % $4,690 +25% +26% $420 +42% +42% *See “Forward-Looking Statements and Non-GAAP Financial Information” Eliquis • Continued U.S. demand growth and marke
Slide 12: Q3 2026 Neuroscience product summary
Not for Product Promotional UseQ3 2026 Results Q3 2026 Neuroscience product summary Global Net Sales $M YoY % Ex-FX* % $168 +5% +5% $57 +33% +33% Cobenfy • Potential new indications to drive next wave of growth • Improving patient experience through prescriber education emphasizing optimized dose ut
Slide 13: Q3 2026 Financial Performance
Not for Product Promotional UseQ3 2026 Results US GAAP Non-GAAP $ in billions, except EPS Q3 2026 Q3 2025 Q3 2026 Q3 2025 Total Revenues, net 13.1 12.2 13.1 12.2 Gross Margin %1 68.3% 71.9% 68.4% 72.9% Operating Expenses2 4.1 4.3 4.1 4.2 Acquired IPR&D 1.6 0.6 1.6 0.6 Amortization of Acquired Intang
Slide 14: Strategic approach to Capital Allocation
Not for Product Promotional UseQ3 2026 Results Strategic approach to Capital Allocation 1. Cash includes cash, cash equivalents and marketable debt securities; 2. Subject to Board approval Cash flow from Operations $B 14 $6.3 $2.0 $1.1 $3.4 $4.2 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 $B Q3 2026 Tot
Slide 15: 2026 Guidance
Not for Product Promotional UseQ3 2026 Results 2026 Guidance* 15 *The Company does not reconcile forward-looking non-GAAP measures. See “Forward-Looking Statements and Non-GAAP Financial Information”; 2026 Guidance excludes the impact of any potential strategic acquisitions, divestitures, specified
Slide 16: Q&A
Chris Boerner, PhD Board Chair, Chief Executive Officer David Elkins Executive VP, Chief Financial Officer Adam Lenkowsky Executive VP, Chief Commercialization Officer Cristian Massacesi, MD Executive VP, Chief Medical Officer, Global Drug Development Q3 2026 Results Q&A